Biodegradable Drug-Polymer Conjugate for Controlled Ocular Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymer-drug conjugates face challenges such as poor control over drug release, limited dose loading, rapid clearance from the body, and complications in regulatory approval due to inactive intermediates, particularly when used for site-specific drug delivery in the eye, where continuous and controlled delivery is desired.
Innovation Solution
A biodegradable drug-polymer conjugate is developed, comprising a copolymer with a three-dimensional network structure formed by triazole moieties, allowing controlled release of drugs like prostaglandins and β-blockers over an extended period, and designed to biodegrade after treatment, ensuring minimal mass loss during use and rapid clearance post-treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If polymer-drug conjugates are used for site-specific drug delivery, then drug delivery precision is improved, but control over drug release becomes difficult
Solution Approach 1:
The patent applies parameter changes by modifying the polymer structure to include specific functional groups (carboxyl, hydroxyl, amino) with controlled densities and types. The polymerization parameters are optimized to achieve desired molecular weights and drug loading capacities, enabling both precise drug delivery to the eye and controlled release kinetics through adjustable polymer-drug interaction parameters.
Solution Approach 2:
The patent uses composite materials by combining biodegradable polymer matrices with drug molecules to form polymer-drug conjugates. The composite structure integrates the polymer's structural integrity and targeting capabilities with the drug's therapeutic function, achieving both precise ocular delivery and controlled release through the synergistic properties of the composite system.
2Quantity of substance
If high drug loading is achieved in the polymer conjugate, then dose loading is improved, but rapid clearance from the body occurs
Solution Approach 1:
The patent applies parameter changes by adjusting the polymer's molecular weight, hydrophilicity-hydrophobicity balance, and degradation rate parameters. These parameter optimizations enable the polymer conjugate to maintain high drug loading capacity while achieving extended circulation time and reduced clearance rate, thereby prolonging the duration of action.
Solution Approach 2:
The patent applies local quality by designing the polymer structure with specific functional groups distributed at different densities and locations. This local differentiation allows regions of the polymer to optimize for drug binding (high loading) while other regions optimize for circulation stability and controlled release, resolving the contradiction between high dose loading and extended duration of action.
3Ease of operation
If the product biodegrades at the target site, then surgical intervention is reduced, but control over treatment timing becomes difficult
Solution Approach 1:
The patent applies parameter changes by carefully selecting and optimizing the polymer's chemical composition, molecular weight, and functional group density to achieve a balance between biodegradability and treatment control. The degradation parameters are tuned so that the polymer remains stable during administration and initial treatment phase, then biodegrades at a controlled rate after drug delivery, minimizing surgical intervention while maintaining treatment timing control.
4Measurement precision
If polymer-drug conjugates are used for ocular delivery, then site-specific delivery is improved, but device complexity increases
Solution Approach 1:
The patent applies local quality by designing the polymer structure with specific functional groups (carboxyl, hydroxyl, amino) at controlled densities and locations. This local differentiation enables the polymer to achieve site-specific ocular delivery through targeted interactions with ocular tissues while maintaining a relatively simple overall conjugate structure that does not significantly increase device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biodegradable drug-polymer conjugate provides controlled drug release and biodegradation, maintaining treatment efficacy while minimizing surgical intervention, addressing issues of patient compliance and drug delivery efficiency in the eye.
Implementation Method 1
designed to biodegrade after treatment, ensuring minimal mass loss during use and rapid clearance post-treatment
Data Source
AI summary
A drug-polymer conjugate, which is a copolymer of at least one monomer of formula (I): (I) where: X may be the same or different at each occurrence and represents a terminal functional group comprising an alkyne or an azide; Q is independently selected at each occurrence and may be present or absent and when present, represents a linking group; R is selected from the group consisting of linear or branched hydrocarbon, optionally substituted aryl and optionally substituted heteroaryl; D is a releasable drug selected from prostaglandins, β-blockers and mixtures thereof; L is a linker group group; and at least one co-monomer of Formula III III J represents a linking functional group, n is 2 to 8, preferably 3 to 8; Y comprises a polyether of formula (ORa)m wherein Ra is independently ethylene, propylene and butylene and m is from 1 to 300 (preferably 2 to 300) and the polyether is in chain with one or more groups which are preferably selected from one or more of optionally substituted straight or branched Ci to do alkylene, amino, ether, ester, amide, carbonate and carbamate; A may be the same or different at each occurrence and represents a group comprising a terminal functional group comprising an alkyne or an azide functionality, wherein said terminal functional group is complementary to the terminal functional group X of formula (I) providing triazole moieties from reaction of X and A.